论文部分内容阅读
Objectives: In order to understand the role of HBV genotypes on the response to the Adefovir dipivoxil(ADV) antiviral therapy.Methods: 178 FBV strains of chronic hepatitis B(CHB) patients treated with ADV had been genotyped.Then, the clinical data were comparatively analyzed based on their genotypes group.Results: The number of genotype B and C were 98 and 80 eases, respectively.Baseline data of both groups of patients were comparable;however, genotype C patients had a higher serum aminotransferase level.Initial Virological Response (IVR) in genotype B and C groups were 33.7% and 30.0% (P>0.05), respectively.At the end of treatment(48W), HBV-DNA level of 41.3% patients with genotype B and 37.6% patients with genotype C were undeteetable(P>0.05).HBeAg seroconversion rates were 22.4% and 18.8% with genotype B and C(P>0.05),respeetively.Conclusions: No significant difference of antiviral response between genotype B and C to ADV therapy has been observed.But, IVR may be an important parameter to predict the antiviral response to ADV therapy.